DRADA is a nuclear enzyme that converts multiple adenosines to isosines in double-helical RNA substrates without apparent intrinsic sequence specificity. In spite of its conservation throughout the animal kingdom, the in vivo role of DRADA has remained obscure since its discovery in 1987. However, our recent findings and studies by others strongly suggest that DRADA acts as a nuclear RNA editing enzyme to regulate the expression of important gene transcripts such as the glutamate-gated ion channel receptors (GluR) of the central nervous system. During the last period of grant support, the applicant succeeded in isolating cDNA clones for DRADA. Using these clones to express recombinant DRADA protein, she and her colleagues have obtained preliminary evidence that demonstrate an involvement of DRADA in GluR RNA editing. In this application, they propose to address questions focussing on the biological functions and natural substrate RNAs of DRADA. Using an established in vitro assay system, they will investigate the mechanism of GluR-B RNA editing in depth, as a model gene system to better understand DRADA action. The interaction of DRADA and GluR-B RNA with an essential co-factor needed for site-selctive editing will be investigated. It is proposed that the co-factor be purified, and its cDNA cloned. The purified co-factor protein will be used to reconstitute the GluR-B RNA editing with DRADA in vitro. The applicant will also determine directly the repertoire of in vivo target RNAs of DRADA. The information gained by the proposed experiments should lead to enhanced understanding of the full range of biological functions of this intriguing nuclear enzyme.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM040536-08
Application #
2684893
Study Section
Neurology C Study Section (NEUC)
Project Start
1991-07-01
Project End
2000-03-31
Budget Start
1998-04-01
Budget End
1999-03-31
Support Year
8
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Nishikura, Kazuko (2017) Oesophageal cancer: RNA editing of SLC22A3 mRNAs: causative relevance to familial ESCC? Nat Rev Gastroenterol Hepatol 14:569-570
Sakurai, Masayuki; Shiromoto, Yusuke; Ota, Hiromitsu et al. (2017) ADAR1 controls apoptosis of stressed cells by inhibiting Staufen1-mediated mRNA decay. Nat Struct Mol Biol 24:534-543
Tan, Meng How; Li, Qin; Shanmugam, Raghuvaran et al. (2017) Dynamic landscape and regulation of RNA editing in mammals. Nature 550:249-254
Song, Chunzi; Sakurai, Masayuki; Shiromoto, Yusuke et al. (2016) Functions of the RNA Editing Enzyme ADAR1 and Their Relevance to Human Diseases. Genes (Basel) 7:
Miyake, Kotaro; Ohta, Toshio; Nakayama, Hisako et al. (2016) CAPS1 RNA Editing Promotes Dense Core Vesicle Exocytosis. Cell Rep 17:2004-2014
Nishikura, Kazuko (2016) A-to-I editing of coding and non-coding RNAs by ADARs. Nat Rev Mol Cell Biol 17:83-96
Gumireddy, Kiranmai; Li, Anping; Kossenkov, Andrew V et al. (2016) The mRNA-edited form of GABRA3 suppresses GABRA3-mediated Akt activation and breast cancer metastasis. Nat Commun 7:10715
Watanabe, Yoshihisa; Yoshimoto, Kanji; Tatebe, Harutsugu et al. (2014) Enhancement of alcohol drinking in mice depends on alterations in RNA editing of serotonin 2C receptors. Int J Neuropsychopharmacol 17:739-51
Ota, Hiromitsu; Sakurai, Masayuki; Gupta, Ravi et al. (2013) ADAR1 forms a complex with Dicer to promote microRNA processing and RNA-induced gene silencing. Cell 153:575-89
Nishikura, Kazuko; Sakurai, Masayuki; Ariyoshi, Kantaro et al. (2013) Antagonistic and stimulative roles of ADAR1 in RNA silencing. RNA Biol 10:1240-7

Showing the most recent 10 out of 37 publications